ACC 22: 5 Trials That Will Change Your Practice with Interventionalist, Dr Mirvat Alasnag

Published: 14 Apr 2022

  • Views:

    Views Icon 810
  • Likes:

    Heart Icon 1
Average (ratings)
No ratings
Your rating

In this short and practice focused review, Dr Mirvat Alasnag (The King Fahd Armed Forces Hospital, Jeddah, SA) highlights some of the late-breaking clinical trials presented at ACC.22 from an interventionalist perspective. 

Trials covered in detail include:
00:58: SODIUM-HF: Study of Dietary Intervention Under 100 Mmol in Heart Failure
01:46: GHATI: Improving STEMI Management Internationally: Two-year Report of 4,015 Patients Enrolled in the American College of Cardiology - Global Heart Attack Treatment Initiative
02:37: Insights From the Corevalve US Pivotal and SURTAVI Trials: Five-year Incidence, Timing and Predictors of Hemodynamic Valve Deterioration of Transcatheter and Surgical Aortic Bioprostheses
03:30: The FLAVOUR Randomized Clinical Trial: Comparison of Fractional Flow Reserve-guided and Intravascular Ultrasound-guided Percutaneous Coronary Intervention in Intermediate Coronary Artery Stenosis
04:34: A Randomized ADAPT-TAVR Trial: Edoxaban Versus Dual Antiplatelet Therapy For Valve Thrombosis and Cerebral Thromboembolism After Transcatheter Aortic-valve Replacement

Recorded on-site at ACC.22, Washington DC. 

Editor: Mirjam Boros

Videography:Tom Green, Dan Brent